Drugs / Perflubutane
Perflubutane
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03578224 | Sep 2018 → Aug 2022 | esophageal disorder | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03009266 | Jul 2018 → Dec 2019 | myocardial ischemia | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02968680 | Apr 2017 → Jun 2019 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03340870 | Oct → Nov 2014 | — | GE Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT00156780 | Aug 2004 → Jul 2005 | chronic obstructive pulmonary disease, congestive heart failure | Acusphere | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02652923 | Jan 2016 → Jan 2022 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02733029 | May 2018 → May 2022 | transplant rejection | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03245255 | Dec 2017 → Sep 2020 | heart failure | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT02398266 | Aug 2016 → Jul 2018 | peripheral arterial disease | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07310758 | Sep 2025 → Sep 2026 overdue | breast cancer, head and neck cancer, melanoma | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05470205 | Nov 2022 → Feb 2028 expected | portal hypertension | Thomas Jefferson University | Recruiting | No outcome recorded |
| Phase 3 | NCT04006275 | Jun → Dec 2019 | cirrhosis of liver, hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT02651090 | Oct 2017 → Mar 2018 | — | Northeastern Ohio Radiology Research and Education Fund | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03335566 | May 2014 → Apr 2015 | liver disorder | GE Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00669851 | Nov 2006 → Mar 2007 | coronary artery disorder | Acusphere | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02489045 | Apr 2015 → Mar 2019 | portal hypertension | Thomas Jefferson University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02737865 | May 2016 → Apr 2019 | focal nodular hyperplasia | Samsung Medical Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-08-10 | Daiichi Sankyo | Regulatory Approval of Additional Indication of Ultrasound Contrast Agent SONAZOID(R) for Injection daiichisankyo.com ↗
Daiichi Sankyo Co., Ltd. announced today that it has received approval in Japan for an additional indication for the ultrasound contrast agent, 16µL vials of SONAZOID® for injection, for the imaging of focal breast lesions. |
| 2006-10-26 | Daiichi Sankyo | Regulatory Ultrasound Contrast Medium Sonazoid ® Gets Import Approval daiichisankyo.com ↗
Tokyo, October 26, 2006 - DAIICHI SANKYO COMPANY, LIMITED has announced today that Japan's Ministry of Labour, Health and Welfare granted wholly owned subsidiary Daiichi Pharmaceutical Co., Ltd. approval for the ultrasound contrast medium Sonazoid® for Injection, a worldwide first. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-08-10 | Daiichi Sankyo | Approval of Additional Indication of Ultrasound Contrast Agent SONAZOID(R) for Injection daiichisankyo.com ↗ |
| 2007-01-10 | Daiichi Sankyo | Ultrasound Contrast Agent Sonazoid(R) for Injection Released for Sale daiichisankyo.com ↗ |
| 2006-10-26 | Daiichi Sankyo | Ultrasound Contrast Medium Sonazoid ® Gets Import Approval daiichisankyo.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Perflubutane | “Sonazoid (Perflubutane)” NCT03578224 ↗ |
| Known as | AI-700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00156780 ↗ |
| Known as | Perflubutano | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104979 ↗ |
| Known as | Sonazoid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03245255 ↗ |
| Modality | Diagnostic / imaging agent | “microbubble contrast agent” NCT02398266 ↗ |
| Route | Intravenous | “administered per package insert (intravenously as a continuous infusion)” NCT02733029 ↗ |